Pyruvate Plays a Main Role in the Antitumoral Selectivity of Cold Atmospheric Plasma in Osteosarcoma.
Por:
Tornin J, Mateu-Sanz M, Rodríguez A, Labay C, Rodríguez R and Canal-Barnils C
Publicada:
23 jul 2019
Ahead of Print:
23 jul 2019
Categoría:
Multidisciplinary
Resumen:
Osteosarcoma (OS) is the most common primary bone tumor but current therapies still have poor prognosis. Cold Atmospheric Plasma (CAP) and Plasma activated media (PAM) have shown potential to eliminate cancer cells in other tumors. It is thought that Reactive Oxygen and Nitrogen species (RONS) in PAM are key players but cell culture media composition alters treatment outcomes and data interpretation due to scavenging of certain RONS. In this work, an atmospheric pressure plasma jet was employed to obtain PAM in the presence or absence of pyruvate and used to treat the SaOS-2 (OS) cell line or hBM-MSC healthy cells. OS cells show higher sensitivity to PAM treatment than healthy cells, both in medium with and without pyruvate, activating apoptosis, DNA damage and deregulating cellular pathways mediated by c-JUN, AKT, AMPK or STAT3. In line with previous works, lack of pyruvate increases cytotoxic potential of PAM affecting cancer and healthy cells by increasing 10-100 times the concentration of H 2 O 2 without altering that of nitrites and thus decreasing CAP anti-tumor selectivity. Suitable conditions for CAP anti-cancer selectivity can be obtained by modifying plasma process parameters (distance, flow, treatment time) to obtain adequate balance of the different RONS in cell culture media.
Filiaciones:
Tornin J:
Biomaterials, Biomechanics and Tissue Engineering Group, Dpt. Materials Science and Metallurgy, Technical University of Catalonia (UPC), Escola d'Enginyeria Barcelona Est (EEBE), c/Eduard Maristany 14, 08019, Barcelona, Spain
Barcelona Research Center in Multiscale Science and Engineering, UPC, Barcelona, Spain
Mateu-Sanz M:
Biomaterials, Biomechanics and Tissue Engineering Group, Dpt. Materials Science and Metallurgy, Technical University of Catalonia (UPC), Escola d'Enginyeria Barcelona Est (EEBE), c/Eduard Maristany 14, 08019, Barcelona, Spain
Barcelona Research Center in Multiscale Science and Engineering, UPC, Barcelona, Spain
Rodríguez A:
Hospital Universitario Central de Asturias - Instituto de Investigación Sanitaria del Principado de Asturias, Av. de Roma s/n, Oviedo, Spain
Labay C:
Biomaterials, Biomechanics and Tissue Engineering Group, Dpt. Materials Science and Metallurgy, Technical University of Catalonia (UPC), Escola d'Enginyeria Barcelona Est (EEBE), c/Eduard Maristany 14, 08019, Barcelona, Spain
Barcelona Research Center in Multiscale Science and Engineering, UPC, Barcelona, Spain
Rodríguez R:
Hospital Universitario Central de Asturias - Instituto de Investigación Sanitaria del Principado de Asturias, Av. de Roma s/n, Oviedo, Spain
Instituto Universitario de Oncología del Principado de Asturias, Av. de Roma s/n, Oviedo, Spain
CIBER oncology (CIBERONC), Madrid, Spain
Canal-Barnils C:
Biomaterials, Biomechanics and Tissue Engineering Group, Dpt. Materials Science and Metallurgy, Technical University of Catalonia (UPC), Escola d'Enginyeria Barcelona Est (EEBE), c/Eduard Maristany 14, 08019, Barcelona, Spain.
Barcelona Research Center in Multiscale Science and Engineering, UPC, Barcelona, Spain.
Open Access
|